Key Publications
Beall Rf, Hollis A, Kesselheim AS, Spackman E. Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based? Value in Health. 2021 Sept; 24 (9), 1328-1334. (2 citations)
*Iragorri N, Hazlewood G, Manns B, Bojke L, Spackman E. Model to Determine the Cost‐Effectiveness of Screening Psoriasis Patients for Psoriatic Arthritis. Arthritis care & research. 2021 Feb; 73 (2), 266-274. (4 citations)
Campbell DJT, Campbell DB, Ogundeji Y, Au F, Beall R, Ronksley PE, Quinn AE, Manns BJ, Hemmelgarn BR, Tonelli M, Spackman E. First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence, and associated costs. Diabetic Medicine. 2021 June; e14622. (2 citations)
*Iragorri N, Hazlewood G, Manns B, Danthurebandara V, Spackman E. (2018). Psoriatic arthritis screening: a systematic review and meta-analysis. Rheumatology. 2018 Oct; key314, https://doi.org/10.1093/rheumatology/key314. (35 citations)
*Iragorri N, Spackman E. Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis. Public Health Reviews. 2018 Dec,39(1):17. (43 citations)
Spackman E, Hinde S, Bojke L, Payne K, Sculpher M. Using cost-effectiveness analysis to quantify the value of genomic-based diagnostic tests: recommendations for practice and research. Genetic Testing and Molecular Biomarkers 2017; Dec:21(12). (8 citations)
McKenna C, Soares M, Claxton K, Bojke L, Griffin S, Palmer S, Spackman E. Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. Value in Health. 2015;18(6). (24 citations)
Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the NICE cost-effectiveness threshold. Health Technol Assess. 2015;19(14). (803 citations)
Hinde S, Spackman E. Bidirectional Citation Searching to Completion: an exploration of literature searching methods. Pharmacoeconomics.2015 Jan;33(1). (78 citations)
Spackman E, Sculpher M, Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, Rees DC, Fijnvandraat K, Kirby-Allen M, Davies S, Williamson L. Cost effectiveness analysis of pre-operative transfusion in patients with Sickle Cell Disease using evidence from the TAPS trial. Eur J Haematol. 2014 Mar;92(3):249-55. (13 citations)
Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, Purohit S, Rees DC, Tillyer L, Walker I, Fijnvandraat K, Kirby-Allen M, Spackman E, Davies SC, Williamson LM. Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS): a randomised controlled multi-centre clinical trial. The Lancet. 2013 Mar;16(381):930–938. (202 citations)